Cardiology

The approval marks the first and only once-daily single-tablet combination therapy for patients with pulmonary arterial hypertension.

Join us April 01 on Twitter for a pre-meeting Tweet chat ahead of the American College of Cardiology's 2024 annual meeting!

New data from NIH investigators show acute respiratory distress syndrome from COVID-19 infection may trigger heart inflammation in patients.

Idorsia Ltd. announced the FDA's approval of aprocitentan (Tryvio) for treatment-resistant hypertension on March 20, 2024.

Eiran Gorodeski, MD, MPH, Parag Goyal, MD, MSc, and James Fang, MD, discuss the HFSA's recent scientific statement on the prevalence and impact of cognitive impairment on the management of heart failure.

Patients whose primary care practitioners were randomized to a clinical decision support system intervention achieved a statistically significant reduction in SBP versus usual care but had similar rates of BP control.

The AccuCinch® System, utilized by Allegheny General Hospital, offers a breakthrough approach to treating heart failure by targeting the left ventricle.

A new study found women (1.64) had a greater hazard ratio of depression for CVD than men (1.39).

Eiran Gorodeski, MD, MPH, discusses a recent scientific statement composed on behalf of the Heart Failure Society of America highlighting the impact of cognitive impairment on patients with heart failure.

On March 08, 2024, the FDA approved semaglutide 2.4 mg (Wegovy) to reduce cardiovascular risk in adults with obesity or overweight and heart disease based on the SELECT trial.

On March 07, 2024, Novo Nordisk provided updates on semaglutide 2.4 mg as well as the development programs cagrisema, monlunabant, and amycretin.

A study suggests that opting for thyroid surgery or radioactive iodine therapy could be better for reducing long-term cardiovascular risk in hyperthyroidism patients compared to medication alone.

In new topline results from the KARDIA-2 trial, zilebesiran added to standard-of-care antihypertensive treatments showed significant reductions in systolic blood pressure.

Novo Nordisk announced topline data from the FLOW trial indicate semaglutide 1.0 mg (Ozempic) was associated with a 24% reduction in risk of kidney disease-related events among individuals with type 2 diabetes and CKD compared to placebo therapy.

An expert cardiologist discusses the importance of healthcare provider education and finding resources around the REMS program.

James L. Januzzi, MD, comments on mavacamten as the first approved cardiac myosin inhibitor for oHCM, balancing the increased risk of heart failure with the medication, and the role of the REMS program.

In this episode, hosts are joined by SURMOUNT-2 principal investigator Timothy Garvey, MD, to discuss the approval of the tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and more.

Our February 2024 cardiology month in review, recaps FDA news, top data from International Stroke Conference and major journals, and perspectives form a bevy of key opinion leaders in the field on hot topics and news from across the spectrum of cardiovascular medicine.

In this episode, hosts are joined by co-chair of the SELECT steering committee A. Michael Lincoff, MD, to discuss results, potential explanations for cardiovascular benefit beyond weight reduction, FLOW trial implications, and the future of incretin therapies.

The approval of the AGENT Drug-Coated Balloon is based on the AGENT IDE trial and was announced by Boston Scientific on March 01, 2024.

A new study found cardiovascular risks can last ≥ 3 years after PM2.5 exposure.

Deepak Bhatt, MD, MPH, looks ahead to discuss what he is most excited about from the upcoming late-breaking clinical trials sessions at the American College of Cardiology 2024 annual meeting

An expert in cardiology shares clinical trial findings of emerging and approved cardiac myosin inhibitors for the treatment of oHCM.

Dr James L. Januzzi reviews the use of cardiac myosin inhibitors for the management of oHCM.

This American Heart Month 2024 feature paints a picture describing the current state of cardiology by asking what the most prevalent and important issues facing the specialty are today from the perspective of 9 leading experts.